Pembrolizumab plus Chemoradiotherapy for locally advanced Cervical Cancer - the prospective, randomized KEYNOTE-A18 Phase 3 Trial

被引：0
|
作者：
Trommer, Maike [1 ,2 ,4 ]
Gaasch, Aurelie [3 ,4 ]
Corradini, Stefanie [3 ]
机构：
[1] Univ klin Koln, Med Fak, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Klin & Poliklin Radioonkol, Kerpener Str 62, D-50937 Cologne, Germany
[2] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Dept Radiat Oncol, Melbourne, Australia
[3] Ludwig Maximilians Univ Munchen, LMU Klin, Klin & Poliklin Strahlentherapie & Radioonkol, Munich, Germany
[4] Arbeitsgruppe junge DEGRO Deutsch Gesell Radioonko, Berlin, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2024年 / 200卷 / 11期
关键词：
D O I：
10.1007/s00066-024-02298-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：994 / 996
页数：3
相关论文
共 50 条
  • [1] ENGOT-CX11/GOG 3047/KEYNOTE-A18: PHASE 3 RANDOMIZED STUDY OF PEMBROLIZUMAB plus CHEMORADIOTHERAPY FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R. L.
    Randall, L. M.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. R.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Yamada, K.
    Puglisi, M.
    Pignata, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A19 - A20
  • [2] Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-StudiePembrolizumab and radiochemotherapy in locally advanced cervical cancer—the prospective, randomised KEYNOTE-A18 phase 3 study
    Maike Trommer
    Aurélie Gaasch
    Stefanie Corradini
    Strahlentherapie und Onkologie, 2024, 200 (11) : 994 - 996
  • [3] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, doubleblind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
    Lorusso, D.
    Xiang, Y.
    Hasegawa, K.
    Scambia, G.
    Galves, M. H. Leiva
    Elias, P. Ramos
    Acevedo, A.
    Vizkeleti, J.
    Gomes, A. J. P. D. S.
    Mejia, F. Contreras
    Reiss, A.
    Ayhan, A.
    Lee, J. Y.
    Saevets, V.
    Zagouri, F.
    Li, K.
    Yamada, K. Ussui
    Toker, S.
    Pignata, S.
    Duska, L. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1279 - S1280
  • [4] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study
    Lorusso, Domenica
    Xiang, Yang
    Hasegawa, Kosei
    Scambia, Giovanni
    Leiva, Manuel
    Ramos-Elias, Pier
    Acevedo, Alejandro
    Vizkeleti, Julia
    Gomes, Andrea
    Mejia, Fernando Contreras
    Reiss, Ari
    Ayhan, Ali
    Lee, Jung-Yun
    Saevets, Valeriya
    Zagouri, Flora
    Li, Kan
    Yamada, Karin
    Toker, Sarper
    Pignata, Sandro
    Duska, Linda R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A2 - A2
  • [5] EUROPEAN NETWORK FOR GYNAECOLOGICAL ONCOLOGICAL TRIAL (ENGOT)-CX11/GYNECOLOGIC ONCOLOGY GROUP (GOG) 3047/KEYNOTE-A18: PHASE 3 TRIAL OF PEMBROLIZUMAB PLUS CHEMORADIOTHERAPY IN HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R. L.
    Randall, L. M.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Yamada, K.
    Puglisi, M.
    Pignata, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A43 - A44
  • [6] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
    Duska, Linda
    Xiang, Yang
    Hasegawa, Kosei
    Scambia, Giovanni
    Leiva, Manuel
    Elias, Pier Anyelo
    Acevedo, Alejandro
    Vizkeleti, Julia
    Juliana Gomes, Andrea
    Contreras Mejia, Fernando
    Reiss, Ari
    Ayhan, Ali
    Lee, Jung-Yun
    Saevets, Valeriya
    Zagouri, Flora
    Li, Kan
    Yamada, Karin
    Toker, Sarper
    Pignata, Sandro
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S8 - S9
  • [7] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R.
    Randall, L.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. R.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Keefe, S.
    Puglisi, M.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1341 - S1342
  • [8] ENGOT-CX11/GOG 3047/KEYNOTE-A18: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
    Lorusso, D.
    Colombo, N.
    Coleman, R.
    Randall, L.
    Duska, L.
    Xiang, Y.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. Raza
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Martin, C.
    Keefe, S.
    Puglisi, M.
    Pignata, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A71 - A71
  • [9] Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (06) : 402 - 402
  • [10] Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies
    How, Jeffrey A.
    Jazaeri, Amir A.
    MED, 2024, 5 (06): : 487 - 489
12345